Literature DB >> 21961647

Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

Min Liu1, Stephanie Kang, Soumya Ray, Justin Jackson, Alexandra D Zaitsev, Scott A Gerber, Gregory D Cuny, Marcie A Glicksman.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2), a large and complex protein that possesses two enzymatic properties, kinase and GTPase, is one of the major genetic factors in Parkinson's disease (PD). Here, we characterize the kinetic and catalytic mechanisms of truncated wild-type (t-wt) LRRK2 and its most common mutant, G2019S (t-G2019S), with a structural interpretation of the kinase domain. First, the substitution of threonine with serine in the LRRKtide peptide results in a much less efficient substrate as demonstrated by a 26-fold decrease in k(cat) and a 6-fold decrease in binding affinity. The significant decrease in k(cat) is attributed to a slow chemical transfer step as evidenced by the inverse solvent kinetic isotope effect in the proton inventory and pL (pH or pD)-dependent studies. The shape of the proton inventory and pL profile clearly signals the involvement of a general base (pK(a) = 7.5) in the catalysis with a low fractionation factor in the ground state. We report for the first time that the increased kinase activity of the G2019S mutant is substrate-dependent. Homology modeling of the kinase domain (open and closed forms) and structural analysis of the docked peptide substrates suggest that electrostatic interactions play an important role in substrate recognition, which is affected by G2019S and may directly influence the kinetic properties of the enzyme. Finally, the GTPase activity of the t-G2019S mutant was characterized, and the mutation modestly decreases GTPase activity without significantly affecting GTP binding affinity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21961647      PMCID: PMC3205922          DOI: 10.1021/bi201173d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  37 in total

1.  LRRK2 mutations in Parkinson disease.

Authors:  M Farrer; J Stone; I F Mata; S Lincoln; J Kachergus; M Hulihan; K J Strain; D M Maraganore
Journal:  Neurology       Date:  2005-09-13       Impact factor: 9.910

2.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.

Authors:  Daniela Berg; Katherine J Schweitzer; Petra Leitner; Alexander Zimprich; Peter Lichtner; Petra Belcredi; Theresa Brüssel; Claudia Schulte; Sylvia Maass; Thomas Nägele; Zbigniew K Wszolek; Thomas Gasser
Journal:  Brain       Date:  2005-12       Impact factor: 13.501

3.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism.

Authors:  Alexandr P Kornev; Nina M Haste; Susan S Taylor; Lynn F Ten Eyck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

4.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

Authors:  Andrew B West; Darren J Moore; Catherine Choi; Shaida A Andrabi; Xiaojie Li; Dustin Dikeman; Saskia Biskup; Zhenshui Zhang; Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2007-01-02       Impact factor: 6.150

5.  Kinase activity of mutant LRRK2 mediates neuronal toxicity.

Authors:  Wanli W Smith; Zhong Pei; Haibing Jiang; Valina L Dawson; Ted M Dawson; Christopher A Ross
Journal:  Nat Neurosci       Date:  2006-09-17       Impact factor: 24.884

6.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Authors:  Genta Ito; Takuro Okai; Go Fujino; Kohsuke Takeda; Hidenori Ichijo; Toshiaki Katada; Takeshi Iwatsubo
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

7.  Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

Authors:  David Gosal; Owen A Ross; Joe Wiley; G Brent Irvine; Janet A Johnston; Mathias Toft; Ignacio F Mata; Jennifer Kachergus; Mary Hulihan; Julie P Taylor; Sarah J Lincoln; Matthew J Farrer; Timothy Lynch; J Mark Gibson
Journal:  Parkinsonism Relat Disord       Date:  2005-09       Impact factor: 4.891

8.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.

Authors:  Luxuan Guo; Payal N Gandhi; Wen Wang; Robert B Petersen; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Exp Cell Res       Date:  2007-07-19       Impact factor: 3.905

9.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

10.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.

Authors:  Naheed L Khan; Shushant Jain; John M Lynch; Nicola Pavese; Patrick Abou-Sleiman; Janice L Holton; Daniel G Healy; William P Gilks; Mary G Sweeney; Milan Ganguly; Vaneesha Gibbons; Sonia Gandhi; Jenny Vaughan; Louise H Eunson; Regina Katzenschlager; Juliet Gayton; Graham Lennox; Tamas Revesz; David Nicholl; Kailash P Bhatia; Niall Quinn; David Brooks; Andrew J Lees; Mary B Davis; Paola Piccini; Andrew B Singleton; Nicholas W Wood
Journal:  Brain       Date:  2005-11-04       Impact factor: 13.501

View more
  15 in total

Review 1.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

2.  Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.

Authors:  Zhiyong Liu; Robert A Galemmo; Kyle B Fraser; Mark S Moehle; Saurabh Sen; Laura A Volpicelli-Daley; Lawrence J DeLucas; Larry J Ross; Jacob Valiyaveettil; Omar Moukha-Chafiq; Ashish K Pathak; Subramaniam Ananthan; Hollis Kezar; E Lucile White; Vandana Gupta; Joseph A Maddry; Mark J Suto; Andrew B West
Journal:  J Biol Chem       Date:  2014-09-16       Impact factor: 5.157

Review 3.  LRRK2 pathobiology in Parkinson's disease.

Authors:  Ian Martin; Jungwoo Wren Kim; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2014-10-10       Impact factor: 5.372

4.  Structural and functional in silico analysis of LRRK2 missense substitutions.

Authors:  Fernando Cardona; Marta Tormos-Pérez; Jordi Pérez-Tur
Journal:  Mol Biol Rep       Date:  2014-02-02       Impact factor: 2.316

5.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

Review 6.  LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Authors:  Yulan Xiong; Valina L Dawson; Ted M Dawson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

Review 7.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

8.  Enzymatic Characterization of ER Stress-Dependent Kinase, PERK, and Development of a High-Throughput Assay for Identification of PERK Inhibitors.

Authors:  Dariusz Pytel; Kathleen Seyb; Min Liu; Soumya S Ray; John Concannon; Mickey Huang; Gregory D Cuny; J Alan Diehl; Marcie A Glicksman
Journal:  J Biomol Screen       Date:  2014-03-05

9.  The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.

Authors:  Soumya Ray; Samantha Bender; Stephanie Kang; Regina Lin; Marcie A Glicksman; Min Liu
Journal:  J Biol Chem       Date:  2014-04-02       Impact factor: 5.157

10.  Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.

Authors:  Bridget A Matikainen-Ankney; Nebojsa Kezunovic; Roxana E Mesias; Yuan Tian; Frances M Williams; George W Huntley; Deanna L Benson
Journal:  J Neurosci       Date:  2016-07-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.